Caribou Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 158
- Market Cap
- -
- Website
- http://www.cariboubio.com
- Introduction
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
Caribou Biosciences Launches Phase 1 Trial of CB-010 in Lupus and Outlines 2025 Milestones
• Caribou Biosciences has initiated the GALLOP Phase 1 trial to evaluate CB-010 in patients with lupus nephritis (LN) and extrarenal lupus (ERL).
• The FDA previously granted Fast Track designation to CB-010 for refractory systemic lupus erythematosus (SLE), expediting its clinical development.
• Caribou plans to present clinical data from multiple programs, including CB-010 in LBCL and CB-011 in multiple myeloma, in H1 2025.
• The company anticipates initiating a pivotal Phase 3 trial for CB-010 in second-line LBCL in H2 2025, pending data confirmation.
AbbVie to Acquire Cerevel, Novartis' Fabhalta Approved, and Other Pharma Updates
• AbbVie is set to acquire Cerevel Therapeutics for $8.7 billion, bolstering its neuroscience pipeline with candidates targeting schizophrenia, Parkinson's disease, and mood disorders.
• The FDA has approved Novartis' Fabhalta (iptacopan), the first oral monotherapy for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.
• Pfizer halted Phase III development of its twice-daily obesity drug, danuglipron, due to significant gastrointestinal side effects observed in Phase II trials.
• Biogen and Eisai received full FDA approval for Leqembi, an Alzheimer's disease drug shown to slow cognitive decline, expanding Medicare coverage.
© Copyright 2025. All Rights Reserved by MedPath